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S U M M A R Y
Objectives: Prior to the advent of therapies with sustained virological response rates of 94%, this study
was conducted for the US Food and Drug Administration (FDA) to assess the safety and efﬁcacy of
ultraviolet blood irradiation (UVBI) for the treatment of hepatitis C virus (HCV) infection.
Methods: Nine patients received 15 UVBI treatments over the course of 22 weeks with the AVIcure
Hemo-modulator, which was modiﬁed from the original Knott Hemo-irradiator. The patients’ viral loads
and liver function tests were obtained periodically during the study and analyzed during the course of
the trial.
Results: At the end of the study, the overall mean reduction in HCV viral load was 21.5% (p = 0.023); on
day 140, direct bilirubin declined by 41.1% (p = 0.0059), aspartate aminotransferase declined by 15.2%
(p = 0.0069), and alanine aminotransferase declined by 19.3% (p = 0.0031). The nadir of the mean and
median viral load occurred on day 259, and it corresponded to a mean viral load reduction of 44.9%
(p = 0.0048). During the course of the study, three patients had a greater than 0.5 log reduction in viral
load (patient 1, 0.56 log reduction on day 259; patient 4, 0.69 log reduction at the end of the study;
patient 11, 0.91 log reduction on day 259). Two patients showed marked improvement in their
concurrent psoriasis at the conclusion of the trial.
Conclusions: In this study, UVBI was safe and had a beneﬁcial effect in the treatment of HCV. This device
should be studied for use in psoriasis and in infectious diseases that have few treatment options. This
article describes a prospective, controlled, phase II clinical trial submitted to the FDA of this device used
for the treatment of HCV infection (Investigational Device Exemption (IDE) #G030242).
 2015 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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Before the advent of therapy for hepatitis C virus (HCV)
infection with sustained virological response (SVR) rates of 94%,1
ultraviolet blood irradiation (UVBI) was proposed as an adjunct
to combination interferon and ribavirin in order to improve
the SVR, which was 50%. This article describes the clinical trial of
HCV patients that was submitted to the US Food and Drug* Corresponding author at: Clinical Laboratories, Charleston Area Medical Center,
Charleston, 3200 MacCorkle Ave. SE, West Virginia, USA. Tel.: +1 304 388 4393.
E-mail address: jtodd.kuenstner@camc.org (J.T. Kuenstner).
http://dx.doi.org/10.1016/j.ijid.2015.06.006
1201-9712/ 2015 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Administration (FDA). After reviewing this clinical trial, the FDA
allowed the sponsoring company to apply for a phase III pivotal trial.
Although the phase III trial was never conducted, this trial is
signiﬁcant because of the potential efﬁcacy of UVBI in the treatment
of other infectious diseases with ineffective or nonexistent therapy.
UVBI was developed by Dr Emmet Knott in 1928,2,3 after Finsen
received the Nobel Prize in 1903 for his ultraviolet light therapy of
the skin in patients with lupus vulgaris, i.e., tuberculosis of the
skin.4,5 Finsen described the treatment of 804 patients with
tuberculosis of the skin and reported that 412 patients were cured
(no recurrence during 2–6 years of observation in 124, or during an
observation time of less than 2 years in 288), 192 patients were
nearly cured, 117 were currently receiving treatment, andciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
Table 1
Preliminary observations for two cases treated with UVBI
Patient Baseline viral
load
(copies/ml)
Final viral
load
(copies/ml)
Method reference
range
(copies/ml)
Treatment
period
A 2464 <200 <200 8 days
B 652 800 Not detectable <100 109 days
UVBI, ultraviolet blood irradiation.
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in 16, death in 44, and unaccounted for in 23 patients).6
Initially, the Knott device was used for the treatment of
bacterial infections. Hancock described seven case histories of
blood stream infection with positive blood cultures, one with colon
bacillus (Escherichia coli), four with hemolytic streptococci, and
two with staphylococci, who recovered following UVBI therapy
alone.7 Miley reported the case of a patient with Staphylococcus
aureus septicemia who recovered following UVBI alone.8 By 1944,
Miley had described an additional 16 cases of staphylococcal
septicemia treated with UVBI. He reported that seven consecutive
patients who had S. aureus septicemia and failed sulfa drugs prior
to UVBI died, but that nine consecutive patients with staphylo-
coccal septicemia (S. aureus in six and Staphylococcus albus
(epidermidis) in three) who had UVBI all recovered.9 Wasson
et al. subsequently conducted a 4-year study of UVBI used alone in
rheumatic fever in 108 children, with 22 consecutive hospitalized
cases of acute rheumatic fever and 86 cases of outpatient acute and
subacute rheumatic fever.10 They observed a rapid subsidence of
the toxic symptoms in 20 of the 22 hospitalized patients, a more
gradual recovery in one patient, and death in one patient. In all
107 surviving patients, they observed only two recurrences, a rate
that compared favorably to sulfa compounds used prophylactical-
ly.
In a case series report of UVBI in eight patients with E. coli
septicemia, six of the eight patients recovered and two patients
died. Of the six who recovered, three had already failed sulfa drugs
(cases 2, 7, and 8) and one surviving patient (case 1) had double
septicemia with E. coli and hemolytic Streptococcus.11
Miley also described the use of UVBI in acute pyogenic
infections.12,13 He described 151 unselected, serial cases over
the course of 3 years, with various acute pyogenic infections for
which a majority received only UVBI and a minority were
chemotherapeutic failures. He reported that 118 patients recov-
ered and 33 patients died and that no patient with infection
uncomplicated by septicemia progressed to a septicemia.13 Miley
and Rebbeck described the results of UVBI in a consecutive series of
72 patients critically ill with peritonitis. Forty-three of these
patients received UVBI and 29 received UVBI after chemothera-
peutic failure. Thirty-two of 40 patients with generalized
peritonitis recovered, 17 of 20 cases of localized peritonitis
recovered, and nine of 12 cases of peritonitis with multiple pelvic
abscesses recovered. In the group of 29 that had already failed
antibiotics, 20 subsequently recovered with UVBI.14 Rebbeck and
Lewis published a case series of six patients with typhoid fever
who were treated with UVBI. The three patients who received
sulfonamide and UVBI had an average recovery time of 51 days and
the three patients who received UVBI alone had an average
recovery time of 24 days. Of the three patients who received
sulfonamide alone, two who survived had a recovery time of
78 days; the third patient in this group died.15
The Knott device was also used to treat viral infections. Miley
and Christensen described the results of UVBI in 79 consecutive
patients with acute viral infections including many cases of polio, a
single case of herpes simplex, herpes zoster, and mumps. They
reported rapid recovery following UVBI in the herpes and mumps
cases as well as in the majority of polio cases.16 In a case series
report from 1955 that predated the identiﬁcation of hepatitis A, B,
and C, Olney described the results of UVBI in 43 patients with acute
viral hepatitis. The patients were classiﬁed as either acute
infectious hepatitis (31 patients) or acute serum hepatitis
(12 patients), and following UVBI, a rapid subsidence of symptoms
with decreasing liver function tests was noted.17 By 1948, over
60 000 blood irradiations had been performed in the USA.16
In a controlled trial, Zhadnov et al. studied 222 patients with
new onset destructive tuberculosis and found that of the86 patients in the treatment group who received combination
UVBI, electrophoresis, and antibiotics, bacterial discharge ceased in
100% and destruction in 89% within 3 months versus 59% and 38%,
respectively, in the control group patients, who received anti-
biotics alone.18 In the controlled trial reported by Shurygin
comparing 25 patients on combination UVBI and antibiotics
versus 37 patients on antibiotics alone, the patients receiving
combination UVBI and antibiotics recovered more rapidly.19
Recently, Kuenstner et al. described several patients who were
treated for infection by Mycobacterium avium subspecies para-
tuberculosis using combination UVBI and antibiotics, with resolu-
tion of Crohn’s disease in one patient and complex regional pain
syndrome in another patient.20
Prior to the development of the treatment protocol used in this
study, a preliminary study of two patients with HCV infection
treated with a predecessor UVBI device showed substantial
reductions in viral load and liver function tests accompanied by
symptomatic improvement. The results are shown in Table 1. For
patient A, the viral load tests were done at Specialty Laboratories
Inc. (Santa Monica, CA, USA) with the PCR RNA Ultraquant method
and the reference range was <200 copies/ml. For patient B, the
viral load tests were done at Medical Diagnostic Laboratories LLC
(Mount Laurel, NJ, USA) by PCR and the reference range was <100
HCV copies/ml serum. Based on these observations and on the
previously cited literature, a phase II study for the FDA was
designed and conducted as described below.
2. Methods
Pilot Study #2 for the Hemo-Modulator for the Reduction of
Viral Load in Patients with Chronic Hepatitis C (CHC) began in
March 2006 under the IDE protocol approved by the FDA in
Supplement 8 on February 21, 2006, and was approved by the
Warren Hospital Institutional Review Board (IRB). The single
investigational site was Warren Hospital, Phillipsburg, NJ, USA.
The inclusion criteria for the trial included the following: (1) a
diagnosis of CHC conﬁrmed by the presence of the antibody to HCV
virus (anti-HCV) by enzyme immunoassay (EIA), and by a positive
anti-HCV by recombinant immunoblot assay (RIBA); (2) a positive
HCV-RNA by reverse transcriptase PCR (RT-PCR) for at least
6 months; (3) subject classiﬁed as a non-responder. A non-
responder was deﬁned as a patient who had detectable HCV-RNA
upon completion of a course of standard pharmacological
treatment (interferon plus ribavirin) or who had failed to maintain
undetectable HCV-RNA for 6 months following the end of
treatment for a standard course of pharmacological treatment.
The exclusion criteria for the trial included the following: (1)
the subject had cirrhosis, hepatocellular carcinoma, or another
liver disease; (2) the subject habitually used excessive alcohol or
illicit drugs; (3) the subject had had a positive test for HIV
conﬁrmed by Western blot obtained within the past 12 months.
Eleven subjects were enrolled in the study and nine completed
the treatment regimen. The patients served as their own controls.
Subjects underwent three sessions of ﬁve ultraviolet blood
irradiation treatments over a 22-week period, with a 6-month
Table 2
Treatment schedule
Week Sunday Monday Tuesday Wednesday Thursday Friday Saturday
1, 10, 20 Treatment 1 Treatment 2
2, 11, 21 Treatment 3 Treatment 4
3, 12, 22 Treatment 5
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the original Knott protocol and is shown in Table 2.
The primary effectiveness measurement of the study was
complete clearance of the virus by the end of the treatment period.
The secondary effectiveness measurements included a reduction in
viral load and a decrease in tests of inﬂammation of the liver (direct
bilirubin, alanine aminotransferase (ALT), and aspartate amino-
transferase (AST)). Both the viral load and the liver function tests
were assessed in two ways: (1) individual improvement, and (2)
overall group improvement.
The primary effectiveness measurements of UVBI treatment
with the Hemo-modulator included a comparison of the baseline
viral load to the viral load at 6 months following the last
treatment for each subject, measured by RT-PCR. Clinical success
was deﬁned as at least 10% of the patients treated (on an intent-
to-treat basis) achieving an undetectable HCV-RNA level
(<40 IU/ml serum) at the end of treatment (week 22) and
maintaining that undetectable level for 6 months after the last
treatment.
A secondary assessment of effectiveness was performed at the
end of the study. The following endpoints were assessed: (1)
percentage of patients achieving a negative HCV-RNA level at each
follow-up point, (2) percentage of patients achieving negative
HCV-RNA at week 22, who maintained undetectable levels through
week 46, and (3) percentage of patients achieving normal liver
function tests at each follow-up point.
The direct bilirubin, AST, and ALT tests were done at the Warren
Hospital laboratory on a Dimension RxL Analyser (Dade Behring
Corp., later acquired by Siemens Healthcare Diagnostics, Inc.,
Newark, DE, USA). The reference ranges were 14–38 IU/l for AST,
24–50 IU/l for ALT, and 0–0.3 mg/dl for direct bilirubin. HCV viral
load testing was done at the Laboratory Corporation of America
(Raritan, NJ, USA). The method used was RT-PCR and the detection
limit was 40 IU/ml serum.
2.1. The AVIcure Hemo-irradiator
The original Knott Hemo-irradiator was redesigned to meet
contemporary safety standards. The lamp was designed to
generate wavelengths between 200 nm and 400 nm, which
encompass the germicidal bands of UVB (280–315 nm) and UVC
(200–280 nm). In addition to the lamp, a light chamber in the
device was engineered to provide consistent exposure among
treatments.
A peristaltic pump that does not come into contact with the
patient’s blood creates a regulated blood ﬂow and reinfusion. Blood
contact only occurs within the enclosed disposable kit. The
disposable kit consists of a reservoir bag and tubing connected to a
blood exposure chamber. The reservoir bag allows for rapid blood
drawing and paced reinfusion, and the blood exposure chamber
provides maximum lamp exposure to the passing blood surface.
The blood passes through the exposure chamber, a continuous
spiral labyrinth that exposes the blood to the UV light. This
efﬁcient design provides maximum exposure to the treated blood
surface. The kit was designed to produce less than 0.07% hemolysis
during the treatment. The volume of treated blood is based on
patient weight, i.e., 1.5 cc/lb (3.3 ml/kg).Blood is collected into a vacuum sterile container prepared with
3000 to 5000 units of heparin sodium. The container is carefully
inverted to mix the blood with the heparin and then hung from an
intravenous (IV) pole attached to the UVBI system. The blood is
then circulated through the exposure chamber, thereby exposing
the blood to UV irradiation at a rate of approximately 30 ml/min.
The irradiated blood is then returned to the patient at the fastest
infusion rate allowed (per a standard administration set). The
duration of the procedure is approximately 20 min.
3. Results
Nine patients completed the treatment regimen and each
received 15 Hemo-modulator treatments. The data from these
patients are presented as the primary data set. Since patient
2 completed 12 of the planned 15 treatments, the data obtained for
this patient are included in several of the analyses as well. Each of
the pre-established success criteria and an analysis of the study
results against these criteria are presented next. With respect to
the primary effectiveness criteria stated above, no patient achieved
an undetectable HCV-RNA level at the end of treatment (week 22)
or at any time recorded throughout the study. With respect to the
secondary effectiveness criteria stated above, the following results
were observed. A one-tailed t-test for paired samples (a = 0.05)
was used for the statistical analyses in Tables 3–6.
3.1. Individual improvement in viral load
Three patients had a greater than 0.5 log reduction in viral load.
Patient 4 exhibited a 0.69 log reduction at the end of the study
(Table 3). On day 259, patient 1 exhibited a 0.56 log reduction and
patient 11 exhibited a 0.91 log reduction (Table 4).
3.2. Overall improvement in viral load
Table 3 shows that there was a mean reduction of 21.5% in the
viral load (p = 0.023) at the end of the study. Note that a tenth
patient (patient 2, who completed 12 of the 15 treatments) is
included in this analysis. Figure 1 shows the variation in mean and
median viral load during the study. From day 0 through 150, the
mean and median viral load increased and then after day 150, it
steadily declined. The nadir of the mean and median viral load
occurred on day 259, and it corresponded to a mean viral load
reduction of 44.9% (p = 0.0048). Note that a tenth patient (patient 2,
who completed 12 of the 15 treatments) is included in this
analysis.
3.3. Individual improvement in liver function tests
Individual liver function results did not meet the secondary
assessment of effectiveness criterion, i.e., normalization of liver
function tests. All patients with the exception of patients 3, 6, 7,
and 13 began the study with elevated AST and ALT and did not
experience a normalization of AST or ALT at any study time point.
The only normalization of a liver function test occurred in patient
4 for direct bilirubin. Note that only one patient began the study
Table 3
Percentage change and log change in viral load, comparing the baseline to the end of study viral load. The baseline viral load was the average of the viral loads on days 14 and
0, while the end of study viral load was the average of the viral loads on days 323 and 327a
Patient Baseline viral
load (IU/ml)
Final viral
load (IU/ml)
% Change in
viral load
Baseline log
viral load
Final log
viral load
Change in log
viral load
1 1 560 000 535 000 65.71% 6.193 5.728 0.46
2 5 665 000 5 630 000 0.62% 6.753 6.751 0.0027
3 1 028 500 1 107 500 +7.68% 6.012 6.044 +0.032
4 2 530 000 518 000 79.53% 6.403 5.714 0.69
6 739 500 1 050 500 +42.06% 5.869 6.021 +0.15
7 3 010 000 2 925 000 2.82% 6.479 6.466 0.012
9 3 140 000 2 730 000 13.06% 6.497 6.436 0.061
11 657 500 313 500 52.32% 5.818 5.496 0.32
12 3 095 000 2 685 000 13.25% 6.491 6.429 0.062
13 4 040 000 2 525 000 37.50% 6.606 6.402 0.20
Mean 2 546 550 2 001 950 21.51% 6.312 6.145 0.163
a Change in viral load: p = 0.023, t-statistic = 2.31. Change in log viral load: p = 0.038, t-statistic = 1.99.
Table 4
Percentage change and log change in viral load, comparing the baseline to the nadir of the viral load. The baseline viral load was the average of the viral loads on days 14 and
0, while the nadir of the viral load occurred on day 259 of the study. Patients 2, 6, and 13 were omitted because they did not have any viral load data for this datea
Patient Baseline viral
load (IU/ml)
Nadir viral
load (IU/ml)
% Change in
viral load
Baseline log
viral load
Nadir log
viral load
Change in log
viral load
1 1 560 000 429 000 72.5 6.19 5.63 0.56
3 1 028 500 1 260 000 +22.5 6.01 6.10 +0.09
4 2 530 000 937 000 63.0 6.40 5.97 0.43
7 3 010 000 2 010 000 33.2 6.47 6.30 0.18
9 3 140 000 2 380 000 24.2 6.49 6.37 0.12
11 657 500 81 800 87.6 5.81 4.91 0.91
12 3 095 000 1 350 000 56.4 6.49 6.13 0.36
Mean 2 145 857 1 206 829 44.9 6.26 5.92 0.35
a Change in viral load: p = 0.0048, t-statistic = 3.73. Change in log viral load: p = 0.015, t-statistic = 2.85.
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bilirubin was not possible for the other patients.
Although the normalization of AST and ALT did not occur for any
patient, consistent and modest declines were observed for some
patients. As shown in Table 5, ﬁve patients showed declines in all
three liver function tests at the end of the study (patients 1, 3, 4, 9,
and 13). On day 140, the nadir of the liver function tests, six
patients had declines in all three liver function tests (patients 1, 3,
4, 7, 9, and 13) (Table 6).
3.4. Overall improvement in liver function tests
Figure 2 shows that the nadir of the decline in liver function
occurred on day 140 rather than at the end of the trial. Table 6
shows that for the group as a whole on day 140, direct bilirubin
declined by 41.1% (p = 0.0059), AST declined by 15.2% (p = 0.0069),Figure 1. Variation in the mean and median viral load over time.and ALT declined by 19.3% (p = 0.0031). Modest declines in liver
function tests were observed at the end of the study as well. Direct
bilirubin declined by 31.4% (p = 0.0016), AST declined by 24.9%
(p = 0.066), and ALT declined by 17.9% (p = 0.105).
3.5. Serious adverse events (AEs)/unanticipated adverse device effects
(UADEs)
Side effects were generally mild and resolved on their own or
with minimal medical attention. The compliance of the patients in
this trial, who all completed all 15 treatment visits on schedule,
even though some had to travel long distances, further demon-
strates that Hemo-modulator treatments are very well tolerated by
patients. A summary of the side effects appears in Table 7.
3.6. Additional ﬁndings
Two patients experienced unanticipated health improvements.
They had mild to severe psoriasis that was unresponsive to other
therapies. Both subjects were noted to have a dramatic improve-
ment in their psoriasis with the UVBI treatments and both were
clear for several months after completion of the full course of UVBI.
One of the two patients (patient 1) had complete remission of their
psoriasis, which had been present for several years. The symptoms
resolved during treatment, reappeared brieﬂy after treatment
cessation, and then resolved completely for the duration of the
follow-up period. The patient was still free of psoriasis as of June
2007, which was more than 9 months from his last UVBI treatment.
4. Discussion
This prospective controlled study of nine patients with HCV
infection demonstrates that UVBI used without other therapy was
Table 5
Percentage change in liver function tests, comparing the baseline to the end of study liver function markers. For each respective liver function test, the baseline was the
average of days 14 and 0, while the end of study was the value of the liver function tests on day 327a
Patient Baseline direct
bilirubin (mg/dl)
Final direct
bilirubin (mg/dl)
% Change direct
bilirubin
Baseline
AST (U/l)
Final
AST (U/l)
% Change
AST
Baseline
ALT (U/l)
Final ALT
(U/l)
% Change
ALT
1 0.15 0.1 33.3 85 53 37.6 156 104 33.3
2 0.1 0.1 0 63 45 28.6 125 77 38.4
3 0.2 0.1 50.0 33 31 6.1 79 62 21.5
4 0.35 0.3 14.3 50 30 40.0 81 65 19.8
6 0.1 0.1 0 46 40 13.0 74 68 8.1
7 0.1 0.1 0 28 11 60.7 49 38 22.4
9 0.2 0.1 50.0 118 64 45.8 282 159 43.6
11 0.15 0.1 33.3 126 159 26.2 204 233 14.2
12 0.3 0.2 33.3 128 136 6.3 221 279 26.2
13 0.1 0 100.0 28 14 50.0 66 45 31.8
Mean 0.175 0.12 31.4 70.5 58.3 24.9 133.7 113 17.9
AST, aspartate aminotransferase; ALT, alanine aminotransferase.
a Liver function tests: direct bilirubin p = 0.0016, t-statistic = 3.97; AST p = 0.066, t-statistic = 1.66; ALT p = 0.105, t-statistic = 1.35.
Table 6
Percentage change in liver function tests, comparing the baseline to the nadir of the liver function tests. For each respective liver function test, the baseline was the average of
days 14 and 0, while the nadir of the liver function tests occurred on day 140a
Patient Baseline
direct bilirubin
(mg/dl)
Nadir direct
bilirubin
(mg/dl)
% Change
direct
bilirubin
Baseline
AST (U/l)
Nadir
AST (U/l)
% Change
AST
Baseline
ALT (U/l)
Nadir
ALT (U/l)
% Change
ALT
1 0.15 0.1 33.3 85 55 35.3 156 95 39.2
2 0.1 0.1 0 63 40 36.6 125 87 30.4
3 0.2 0.1 50.0 33 29 12.2 79 68 14.0
4 0.35 0.2 42.9 50 48 4.0 81 70 13.6
6 0.1 0.1 0 46 31 32.7 74 59 20.3
7 0.1 0 100.0 28 27 4.0 49 42 14.3
9 0.2 0.1 50.0 118 93 21.2 282 224 21.6
11 0.15 0.2 +33.3 126 125 1.0 204 169 17.2
12 0.3 0.1 67.7 128 126 2.0 221 225 +2.0
13 0.1 0 100.0 28 22 2.5 66 50 24.3
Mean 0.175 0.1 41.1 70.5 59.6 15.2 133.7 108.9 19.3
AST, aspartate aminotransferase; ALT, alanine aminotransferase.
a Liver function tests: direct bilirubin p = 0.0059, t-statistic = 3.14; AST p = 0.0069, t-statistic = 3.05; ALT p = 0.0031, t-statistic = 3.55.
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Figure 2. Variation in the mean liver function tests over time.
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Table 7
Summary of anticipated and unanticipated adverse effects
Anticipated and unanticipated adverse effects Frequency
Serious and/or unanticipated adverse events
Vasovagal episode 1
Porphyria cutanea tarda (determined not due to UVBI) 1
Adverse events
Headache 1
Hot ﬂashes 3a
Body rash 1
Urinary tract infection 1
Hematoma at post treatment lab access site 1
UVBI, ultraviolet blood irradiation.
a All three for the same patient (patient 7).
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in HCV viral load and a reduction in inﬂammatory markers. During
the course of the study, three patients had a greater than 0.5 log
reduction in viral load (patient 1, 0.56 log reduction on day 259;
patient 4, 0.69 log reduction at the end of the study; patient 11,
0.91 log reduction on day 259). These results are unlikely due to
expected random ﬂuctuation in viral load. HCV-RNA rarely varies
by more than 1 log and in most cases the variation is less than
0.5 log.21 For the entire group, by the end of the study, there was a
reduction in HCV viral load of 21.5% (p = 0.023); on day 140, direct
bilirubin declined by 41.1% (p = 0.0059), AST declined by 15.2%
(p = 0.0069), and ALT declined by 19.3% (p = 0.0031). For many of
the patients (patients 1, 3, 4, 9, and 13), declines in the viral load
occurred with declines in all three liver function tests.
A proper analysis of these results would compare UVBI to
monotherapy such as sofosbuvir or lepidasvir used alone. In this
scenario, although treatment with sofosbuvir results in HCV viral
load declines of 5 to 6 log, this therapy is also subject to treatment
failure when used alone due to the development of viral resistance.
The mechanism of action of UVBI is incompletely understood.
Ultraviolet light in the C region (UVC) inactivates bacterial and viral
pathogens present in the blood that is irradiated. In the case of
bacteria and DNA viruses, UVC induces the formation of thymine–
thymine dimers that prevent replication.22 In the case of RNA
viruses, UVC induces the formation of uracil–uracil dimers that also
prevent replication.23 Bacteria can repair ultraviolet light-induced
damage and normal lymphocytes also have repair mechanisms.24,25
Because only 200 ml of blood in an average adult (or 4% of the
total 5.0-l blood volume) is treated during a session of UVBI, factors
other than pathogen inactivation, such as enhancing innate
immunity, are likely responsible for the beneﬁt. A detailed
discussion of potential mechanisms of action is found in an article
by Kuenstner et al.20
Two of the patients in this trial had concurrent psoriasis and
showed marked improvement in this condition by the end of the
trial. A clinical trial of UVBI is planned for patients with psoriasis.
Based on this prospective clinical trial in hepatitis C infection
and the numerous case series reports in other infectious diseases,
this device should be studied as a standalone or adjunctive therapy
for infectious diseases that emerge and for others without effective
therapy. Such diseases include multidrug-resistant Mycobacterium
tuberculosis, multidrug-resistant Salmonella typhi, Mycobacterium
avium complex including subspecies paratuberculosis, and dengue,
chikungunya, Ebola, Marburg, West Nile, and inﬂuenza viruses. A
study of the efﬁcacy of UVBI in monkeys infected with simian
immunodeﬁciency virus has been performed and showed positive
results; this will be submitted for publication. Finally, further
studies using UVBI adjunctively to treat human infection with
Mycobacterium avium complex including subspecies paratubercu-
losis will be conducted in the near future.Acknowledgements
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